scholarly article | Q13442814 |
P356 | DOI | 10.1016/S1470-2045(12)70566-1 |
P698 | PubMed publication ID | 23312888 |
P50 | author | Tadeusz Pieńkowski | Q38290512 |
P2093 | author name string | Christoph Zielinski | |
Bella Kaufman | |||
Istvan Lang | |||
Diethelm Messinger | |||
Richard Greil | |||
Bohuslav Melichar | |||
Salomon M Stemmer | |||
Günther G Steger | |||
Thomas Brodowicz | |||
Zanete Zvirbule | |||
Zsuzsanna Kahan | |||
Semir Beslija | |||
Central European Cooperative Oncology Group | |||
Daniela Sirbu | |||
Larisa Ryvo | |||
P2860 | cites work | Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? | Q44874881 |
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer | Q44963911 | ||
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer | Q47701435 | ||
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer | Q48636986 | ||
Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects. | Q53105911 | ||
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q59567521 | ||
Progress against solid tumors in danger: the metastatic breast cancer example | Q59616684 | ||
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial | Q33391647 | ||
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer | Q33561160 | ||
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | Q34022546 | ||
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study | Q34172753 | ||
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial | Q36197026 | ||
Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? | Q37717833 | ||
1st International consensus guidelines for advanced breast cancer (ABC 1). | Q37994463 | ||
P433 | issue | 2 | |
P921 | main subject | bevacizumab | Q413299 |
capecitabine | Q420207 | ||
paclitaxel | Q423762 | ||
metastatic breast cancer | Q12859063 | ||
phase III clinical trial | Q42824827 | ||
P304 | page(s) | 125-133 | |
P577 | publication date | 2013-01-10 | |
P1433 | published in | Lancet Oncology Commission | Q13747613 |
P1476 | title | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. | |
P478 | volume | 14 |